Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.66%
#2 Venom Venom +22.52%
#3 aelf aelf +12.97%
#4 TRIA TRIA +8.74%
#5 Decred Decred +7.98%
#6 Status Status +7.87%
#7 DexNet DexNet +7.56%
#8 MarsCoin MarsCoin +7.36%
#9 Pons Pons +7.15%
#10 Wibx Wibx +5.97%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Cell MedX Corp. Cell MedX Corp.

Cell MedX Corp.

CMXC
Kedudukan dalam Saham #30406
Cell MedX Corp. is a biotechnology firm dedicated to identifying, developing,... Cell MedX Corp. is a biotechnology firm dedicated to identifying, developing, and marketing both therapeutic and non-therapeutic solutions aimed at individuals suffering from conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and various kidney-related ailments. The company's offerings include the eBalance Pro System, designed for clinical application by medical professionals, and the eBalance Home System, intended for personal use to promote general well-being and alleviate pain. Both systems are managed by the eBalance Console, a central control unit featuring three distinct pre-programmed microcurrent algorithms: wellness, pain management, and a dual mode. Originally established in 2010 as Sports Asylum, Inc., the company adopted its current name, Cell MedX Corp., in September 2014. Its operations are headquartered in Carson City, Nevada.
Harga Saham
$0.41
Disegerakkan terakhir: 2024-12-24
Modal Pasaran
$16.96M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Cell MedX Corp. (CMXC)

Kategori

Healthcare
Pendapatan untuk Cell MedX Corp. (CMXC)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Cell MedX Corp., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Cell MedX Corp. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
$7.51B -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
$5.15B -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
$5.56B -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
$3.86B -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
$1.42B -
US